Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Jan 05, 2022 7:29pm
608 Views
Post# 34287429

RE:Science stuff

RE:Science stuffHi Dawg - I think there are 2 key features to Theralase's pdt which makes it a game changer - the selective uptake of the photosensitizer by cancer cells (which, as you note below, rely on the over-expression of transferrin receptors on cancer vs normal cells) and the inducement of immunogenic cell death, which establishes antitumour immunity, so that any cancer cells, of the type destroyed, which escape the therapy are hunted down and destroyed by the patient's own immune system.

An extremely important recent paper by Dr. McFarland discusses how a new class of potent Rutherrin based photosensitizers not only destroys melanoma cells, but demonstrably induces immunogenic cell death. At the risk of being hyperbolic, a treatment based on this photosensitizer might end up being an actual cure for melanoma.

"In summary, our results show that Ru PDT (with clinically approved red light) produces clinically desired anticancer attack on melanoma via two-prongs: 1) by causing direct cytotoxicity in melanoma cells, and 2) via ICD-mediated generation of protective antitumor immunity [Figure 1b]. Such a Ru PDT-induced and non-exclusive two-pronged attack on cancers can be harnessed not only to eradicate existing cancer cells but also to establish protection against possible cancer relapse."

Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy


DJDawg wrote:
Just doing some random reading and found this. Likely posted before. It is an article talking about the over-expression of transferrin receptors on cancer vs normal cells. This receptor is what would take up Rutherrin based molecules preferentially and then, when activated by xray or light, cause cell death. I liked the image (link below) which showed the dramatic difference in TFR1 expression between normal and cancer cells. Makes you appreciate how powerful TLT's compounds may be in terms of targetting proliferating cancers selectively. Truly could be game changer.

https://postimg.cc/G4NNHz0V

image is from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048407/pdf/ajcr0008-0916.pdf


<< Previous
Bullboard Posts
Next >>